Today: 15 May 2026
Why POET Technologies Stock Jumped After a $50 Million Lumilens AI Optics Order
15 May 2026
2 mins read

Why POET Technologies Stock Jumped After a $50 Million Lumilens AI Optics Order

San Jose, California, May 15, 2026, 01:10 (PDT)

Shares of POET Technologies Inc. surged after Lumilens Inc. submitted a $50 million initial order linked to a new partnership focused on AI networking—a commercial milestone for the optical-components maker following a stretch of choppy trading. According to both companies, the supply deal has the potential to exceed $500 million in purchases over a five-year span.

Order’s suddenly a bigger deal, with POET still working to prove its photonics platform can scale beyond small revenue. For the first quarter, the company posted $503,389 in non-recurring engineering and product revenue, booked a $12.3 million net loss, and saw operating cash flow in the red by $8.8 million.

Lumilens changed the tone for investors. POET shares on Nasdaq finished Thursday at $20.57—an eye-catching 43.15% jump. By early extended trading on Friday, they had climbed again to $21.62, according to MarketBeat data.

POET and Lumilens are collaborating on what’s called an Electrical-Optical Interposer, or EOI, platform. Basically, this packaging method is designed to position electronic and photonic—meaning light-based—components in much closer proximity. The idea: help AI data-center systems handle bigger data loads at higher speeds, and reduce the stress compared to traditional electrical connections.

“GPU interconnects are emerging as the defining bottleneck for scaling AI,” said Ankur Singla, founder and CEO of Lumilens. For POET, Chief Executive Suresh Venkatesan put it this way: the tie-up is about applying “semiconductor-style manufacturing discipline to optical engines.” Securities and Exchange Commission

Lumilens picked up a warrant allowing it to purchase as many as 22.9 million POET common shares at $8.25 apiece over a nine-year stretch. Right away, 2.29 million of those shares can be exercised; the remainder vest in chunks, linked to Lumilens making payments on future purchase orders.

But there’s no guaranteed revenue yet. POET expects engineering samples by late 2026, with a production ramp timed to hyperscale customer rollouts in 2027. Whether fulfillment and revenue come through will hinge on hitting targets in development, module qualification, and scaling up manufacturing.

The warning comes after a tough stretch. On April 27, POET disclosed that Marvell Semiconductor scrapped every purchase order with Celestial AI, including those for initial production, arguing POET violated confidentiality rules around order and shipping details.

Competition is heating up. Back in December, Reuters reported Marvell’s $3.25 billion acquisition of Celestial AI, a move that brought photonics tech into Marvell’s fold for next-gen data centers—putting it even more directly up against Broadcom and Nvidia as hyperscalers hunt for speedier, greener AI.

Venkatesan, in POET’s earnings statement, pointed to deals with LITEON, Lessengers and Lumilens as proof that demand is picking up for the Optical Interposer platform. He described the Lumilens deal as an “important commercial milestone”—a phrase that puts the spotlight on whether those words translate into actual orders, shipments and cash flow. GlobeNewswire

POET is bringing in more operational muscle. The company announced this week that Sandeep Kumar, who previously ran operations at Silicon Labs, will step in as chief operating officer starting May 11. Venkatesan said Kumar’s main task will be ramping up manufacturing hires in Malaysia, aiming to get the site ready for high-volume output.

POET now faces the tougher task of delivering, not just talking up demand. Landing the Lumilens deal puts a bigger commercial goal on the table, yet with the timeline stretching out to 2027, and a first-quarter loss still weighing, the price of reaching that target is clear.

Stock Market Today

  • Key Advice for Investors: Focus on Long-Term Market Investment, Not Short-Term Fluctuations
    May 15, 2026, 6:19 AM EDT. The stock market has confounded many investors with strong returns despite economic challenges, including inflation and geopolitical tensions. The S&P 500 gained about 33% in the past year, the Dow rose roughly 23%, and the Nasdaq surged 47%. Experts caution against trying to predict short-term movements, which are highly volatile and influenced by unpredictable factors like trade tensions and supply disruptions. Historically, holding an investment such as an S&P 500 fund for longer periods significantly reduces the risk of losses. Short-term trading can result in locked-in losses and missed recovery gains, as illustrated by hypothetical scenarios involving the Vanguard S&P 500 ETF (VOO). Data shows one-year periods see negative returns 33% of the time, but this risk declines sharply over five- and ten-year horizons. Investors are advised to prioritize time in the market over timing it to enhance potential returns.

Latest articles

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

15 May 2026
Mobix Labs shares jumped 78.74% to $3.11 Thursday after it signed a non-binding letter of intent to acquire Special Project Delivery, a U.S. critical-minerals and energy-storage platform. The company also amended a convertible note with Leviston Resources, raising principal to $4 million for $833,000 in new cash. SPD was formed in 2019 and is based in Newport Beach, California.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

15 May 2026
HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

15 May 2026
MicroAlgo Inc. announced a new algorithm for automating quantum circuit design, sending its shares up 13.18% to $4.55 at Thursday’s close and 20.88% higher in pre-market trading Friday. The company said its tool can generate and evaluate quantum circuits without pre-set specs and tested it on standard problems, but did not disclose customers, pricing, or a launch date.
Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

15 May 2026
Datavault AI shares climbed about 10% in early premarket trading ahead of its first-quarter results and webcast. The move follows a Senate committee vote advancing a crypto-market bill tied to Datavault’s tokenization strategy. The company recently raised $60 million in a stock sale to fund its GPU edge-network plan, raising dilution concerns. Shares were quoted at $0.5861, up from $0.55 in the recent offering.
Cerebras Stock Extends Its IPO Surge — The Valuation Catch Behind CBRS’s 68% Debut
Previous Story

Cerebras Stock Extends Its IPO Surge — The Valuation Catch Behind CBRS’s 68% Debut

Nu Holdings Q1 Earnings: Nubank’s $5 Billion Quarter Has a Catch — Credit Risk
Next Story

Nu Holdings Q1 Earnings: Nubank’s $5 Billion Quarter Has a Catch — Credit Risk

Go toTop